195 related articles for article (PubMed ID: 24608632)
1. Differences in expression of uroplakin III, cytokeratin 7, and cyclooxygenase-2 in canine proliferative urothelial lesions of the urinary bladder.
Sledge DG; Patrick DJ; Fitzgerald SD; Xie Y; Kiupel M
Vet Pathol; 2015 Jan; 52(1):74-82. PubMed ID: 24608632
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical detection of uroplakin III, cytokeratin 7, and cytokeratin 20 in canine urothelial tumors.
Ramos-Vara JA; Miller MA; Boucher M; Roudabush A; Johnson GC
Vet Pathol; 2003 Jan; 40(1):55-62. PubMed ID: 12627713
[TBL] [Abstract][Full Text] [Related]
3. Significance of uroplakin III expression in recurrence of solitary muscle non-invasive bladder cancer.
Tadin T; Krpina K; Štifter S; Babarović E; Jonjić N
Pathol Res Pract; 2014 May; 210(5):279-84. PubMed ID: 24553301
[TBL] [Abstract][Full Text] [Related]
4. Epithelial urinary bladder tumors from cows with enzootic hematuria: structural and cell cycle-related protein expression.
Cota JB; Carvalho T; Pinto C; Peleteiro MC
Vet Pathol; 2014 Jul; 51(4):749-54. PubMed ID: 23978839
[TBL] [Abstract][Full Text] [Related]
5. Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants.
Li W; Liang Y; Deavers MT; Kamat AM; Matin SF; Dinney CP; Czerniak B; Guo CC
Am J Clin Pathol; 2014 Dec; 142(6):864-71. PubMed ID: 25389341
[TBL] [Abstract][Full Text] [Related]
6. [Plasmacytoid urothelial carcinoma of the urinary bladder: a clinicopathologic study of 16 cases].
Zhang W; Jiang YX; Liu Y; Yu WJ; Zhao H; Li YJ
Zhonghua Bing Li Xue Za Zhi; 2013 Jul; 42(7):433-7. PubMed ID: 24246859
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical Expression of Cyclin D1, Cytokeratin 20, and Uroplakin III in Proliferative Urinary Bladder Lesions Induced by o-Nitroanisole in Fischer 344/N Rats.
Willson CJ; Flake GP; Sills RC; Kissling GE; Cesta MF
Vet Pathol; 2016 May; 53(3):682-90. PubMed ID: 26319780
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical evaluation of novel and traditional markers associated with urothelial differentiation in a spectrum of variants of urothelial carcinoma of the urinary bladder.
Paner GP; Annaiah C; Gulmann C; Rao P; Ro JY; Hansel DE; Shen SS; Lopez-Beltran A; Aron M; Luthringer DJ; De Peralta-Venturina M; Cho Y; Amin MB
Hum Pathol; 2014 Jul; 45(7):1473-82. PubMed ID: 24780825
[TBL] [Abstract][Full Text] [Related]
9. A newly developed uroplakin II antibody with increased sensitivity in urothelial carcinoma of the bladder.
Hoang LL; Tacha DE; Qi W; Yu C; Bremer RE; Chu J; Haas TS; Cheng L
Arch Pathol Lab Med; 2014 Jul; 138(7):943-9. PubMed ID: 24978921
[TBL] [Abstract][Full Text] [Related]
10. Urothelial umbrella cells of human ureter are heterogeneous with respect to their uroplakin composition: different degrees of urothelial maturity in ureter and bladder?
Riedel I; Liang FX; Deng FM; Tu L; Kreibich G; Wu XR; Sun TT; Hergt M; Moll R
Eur J Cell Biol; 2005 Mar; 84(2-3):393-405. PubMed ID: 15819416
[TBL] [Abstract][Full Text] [Related]
11. Uroplakin-III to distinguish primary vulvar Paget disease from Paget disease secondary to urothelial carcinoma.
Brown HM; Wilkinson EJ
Hum Pathol; 2002 May; 33(5):545-8. PubMed ID: 12094381
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. World/Health Organization/Internattional Society of Urologic Pathology.
Alsheikh A; Mohamedali Z; Jones E; Masterson J; Gilks CB
Mod Pathol; 2001 Apr; 14(4):267-72. PubMed ID: 11301341
[TBL] [Abstract][Full Text] [Related]
13. Selective immunohistochemical markers to distinguish between metastatic high-grade urothelial carcinoma and primary poorly differentiated invasive squamous cell carcinoma of the lung.
Gruver AM; Amin MB; Luthringer DJ; Westfall D; Arora K; Farver CF; Osunkoya AO; McKenney JK; Hansel DE
Arch Pathol Lab Med; 2012 Nov; 136(11):1339-46. PubMed ID: 23106579
[TBL] [Abstract][Full Text] [Related]
14. Loss of uroplakin III expression is associated with a poor prognosis in patients with urothelial carcinoma of the upper urinary tract.
Ohtsuka Y; Kawakami S; Fujii Y; Koga F; Saito K; Ando N; Takizawa T; Kageyama Y; Kihara K
BJU Int; 2006 Jun; 97(6):1322-6. PubMed ID: 16686732
[TBL] [Abstract][Full Text] [Related]
15. Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas.
Parker DC; Folpe AL; Bell J; Oliva E; Young RH; Cohen C; Amin MB
Am J Surg Pathol; 2003 Jan; 27(1):1-10. PubMed ID: 12502922
[TBL] [Abstract][Full Text] [Related]
16. Loss of adipocyte-type fatty acid binding protein and other protein biomarkers is associated with progression of human bladder transitional cell carcinomas.
Celis JE; Ostergaard M; Basse B; Celis A; Lauridsen JB; Ratz GP; Andersen I; Hein B; Wolf H; Orntoft TF; Rasmussen HH
Cancer Res; 1996 Oct; 56(20):4782-90. PubMed ID: 8840999
[TBL] [Abstract][Full Text] [Related]
17. Sarcomatoid Urothelial Carcinoma of the Bladder: Analysis of 28 Cases With Emphasis on Clinicopathologic Features and Markers of Epithelial-to-Mesenchymal Transition.
Sanfrancesco J; McKenney JK; Leivo MZ; Gupta S; Elson P; Hansel DE
Arch Pathol Lab Med; 2016 Jun; 140(6):543-51. PubMed ID: 27031776
[TBL] [Abstract][Full Text] [Related]
18. Invasive micropapillary urothelial carcinoma of the bladder.
Lopez-Beltran A; Montironi R; Blanca A; Cheng L
Hum Pathol; 2010 Aug; 41(8):1159-64. PubMed ID: 20381120
[TBL] [Abstract][Full Text] [Related]
19. High expression level of preoperative serum Uroplakin III is associated with biologically aggressive bladder cancer.
Tsumura H; Matsumoto K; Ikeda M; Yanagita K; Hirano S; Hagiwara M; Nagashio R; Fujita T; Sato Y; Iwamura M
Asian Pac J Cancer Prev; 2015; 16(4):1539-43. PubMed ID: 25743828
[TBL] [Abstract][Full Text] [Related]
20. Immunoreactivity of p63 in monolayered and in vitro stratified human urothelial cell cultures compared with native urothelial tissue.
Feil G; Maurer S; Nagele U; Krug J; Bock C; Sievert KD; Stenzl A
Eur Urol; 2008 May; 53(5):1066-72. PubMed ID: 17980954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
